Physician profile
Jonathan A Zelken
NPI 1659548691
$1,908.39
in general payments reported to CMS, 2019-2025
11 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $982 · 2020: $470 · 2021: $174 · 2022: $136 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $147.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $781.58 | 2019-2022 | |
| Merz North America, INC. | $269.00 | 2019 | |
| Tepha INC | $208.77 | 2019 | |
| Galderma Laboratories, L.P. | $157.26 | 2019-2021 | |
| Abbvie INC. | $147.25 | 2025 | |
| Smith+Nephew, INC. | $140.90 | 2020 | |
| Musculoskeletal Transplant Foundation INC. | $96.06 | 2019 | |
| Sientra, INC. | $68.43 | 2020 | |
| Acelrx Pharmaceuticals, INC. | $16.17 | 2020 | |
| Depuy Synthes Sales INC. | $12.95 | 2020 | |
| Apyx Medical Corporation | $10.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Zelken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.